Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Crit Care Med. 2018 Oct;46(10):1634-1642. doi: 10.1097/CCM.0000000000003264.
Vancomycin-resistant enterococci are important pathogens for healthcare-associated infections. Although linezolid is bacteriostatic and daptomycin is rapidly bactericidal against vancomycin-resistant enterococci in vitro, it is not clear whether they differ in their effect on bacterial clearance in patients with vancomycin-resistant enterococci bloodstream infections.
Prospective observational study.
Two university hospitals and research laboratory.
Patients with vancomycin-resistant enterococci bloodstream infection proven by blood cultures were prospectively enrolled from January 2010 to July 2015.
Sequential blood samples were collected. Real-time quantitative polymerase chain reaction was used to monitor bacterial loads.
One hundred eight patients with vancomycin-resistant enterococci bloodstream infection were enrolled. Quantitative polymerase chain reaction assays were performed on 465 blood isolates. We found this method to be closely correlated with colony-forming units and more sensitive than culture. Sixty-three patients (58.3%) received "conventional dose" daptomycin (6-9 mg/kg), 15 (13.9%) received high-dose daptomycin (≥ 9 mg/kg), and 30 (27.8%) were treated with linezolid (600 mg every 12 hr) as sole agents. The initial mean bacterial load was 1.03 log10 copies/mL and unrelated to survival. Survivors had a more rapid early bacterial clearance than nonsurvivors (Δ log10 copies/mL/d; -0.16 vs 0.31; p = 0.02). Multivariable logistic regression showed that a slower early bacterial clearance independently predicted increased mortality (odds ratio, 3.21; 95% CI, 1.03-10.02; p = 0.045). Conventional dose daptomycin was associated with a significantly slower rate of bacterial clearance than high-dose daptomycin (Δ log10 copies/mL/d; -0.04 vs -0.41; p < 0.001) and linezolid (-0.04 vs -0.56; p = 0.043).
We found that survivors of vancomycin-resistant enterococci bloodstream infection had a significantly more rapid early bacterial clearance by quantitative polymerase chain reaction than nonsurvivors. High-dose daptomycin and linezolid were associated with more rapid bacterial clearance than conventional dose daptomycin. These results support recommendations that conventional dose daptomycin not be used for the treatment of patients with vancomycin-resistant enterococci bloodstream infection.
耐万古霉素肠球菌是医院获得性感染的重要病原体。虽然利奈唑胺在体外对耐万古霉素肠球菌具有抑菌作用,达托霉素具有快速杀菌作用,但尚不清楚它们在治疗耐万古霉素肠球菌血流感染患者时对细菌清除率的影响是否存在差异。
前瞻性观察性研究。
两所大学医院和一个研究实验室。
2010 年 1 月至 2015 年 7 月前瞻性纳入经血培养证实为耐万古霉素肠球菌血流感染的患者。
连续采集血样。实时定量聚合酶链反应用于监测细菌负荷。
共纳入 108 例耐万古霉素肠球菌血流感染患者。对 465 份血培养分离株进行了实时定量聚合酶链反应检测。我们发现该方法与集落形成单位密切相关,比培养法更敏感。63 例(58.3%)患者接受“常规剂量”达托霉素(6-9mg/kg),15 例(13.9%)接受高剂量达托霉素(≥9mg/kg),30 例(27.8%)单独使用利奈唑胺(每 12 小时 600mg)治疗。初始平均细菌负荷为 1.03log10 拷贝/ml,与存活率无关。存活者的早期细菌清除速度快于非存活者(Δlog10 拷贝/ml/d;-0.16 与 0.31;p=0.02)。多变量逻辑回归显示,早期细菌清除速度较慢是死亡率增加的独立预测因素(优势比,3.21;95%置信区间,1.03-10.02;p=0.045)。与高剂量达托霉素(Δlog10 拷贝/ml/d;-0.04 与-0.41;p<0.001)和利奈唑胺(-0.04 与-0.56;p=0.043)相比,常规剂量达托霉素与细菌清除率明显较慢相关。
我们发现,耐万古霉素肠球菌血流感染幸存者的早期细菌清除速度通过实时定量聚合酶链反应明显快于非幸存者。高剂量达托霉素和利奈唑胺与常规剂量达托霉素相比,能更快地清除细菌。这些结果支持不推荐常规剂量达托霉素治疗耐万古霉素肠球菌血流感染患者的建议。